Cinitapride PCD Pharma Franchise Company
Cafoli Lifecare offers a Cinitapride range of 3 formulations across tablets and capsules, manufactured in WHO-GMP certified facilities. Distributors building a gastro portfolio can secure district-wise monopoly franchise rights on this widely prescribed prokinetic molecule.
What is Cinitapride?
Cinitapride is a gastroprokinetic agent that acts on serotonin (5-HT4 agonist and 5-HT2 antagonist) and dopamine D2 receptors to enhance gastric motility and accelerate gastric emptying. It relieves symptoms of delayed emptying and reflux. Compound details are available on PubChem.
Therapeutic Applications
Cinitapride is used for functional dyspepsia, gastro-oesophageal reflux disease, bloating, early satiety and non-ulcer dyspepsia, often combined with a proton pump inhibitor. Prescribers include gastroenterologists, general physicians and consultant physicians.
Why Cinitapride is a High-Potential Molecule for Distributors
Gastrointestinal complaints are among the most frequent reasons for OPD visits in India, and prokinetic-plus-PPI combinations are a standard prescription for acidity and dyspepsia. Cinitapride courses run for weeks, generating repeat sales, and its combination formats let partners serve a mass-volume segment with strong prescriber familiarity and quick uptake.
Why Choose Cafoli Lifecare
Cafoli Lifecare is a WHO-GMP compliant, DCGI-approved PCD pharma company with 1000+ franchise partners across India. Partners receive district-wise monopoly rights, promotional inputs including visual aids, MR bags and product cards, and consistent stock availability backed by quality-tested manufacturing.
References
- PubChem: Cinitapride
- PubMed: Cinitapride in functional dyspepsia
Our formulations of Cinitapride find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: